These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 5012204)
21. Controlling the quality of Uncle Sam's drugs. Hecht A FDA Consum; 1977 May; 11(4):22-3. PubMed ID: 10316531 [No Abstract] [Full Text] [Related]
22. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories. Jimenez FA Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711 [No Abstract] [Full Text] [Related]
23. Public standards for drugs: reflections on their use by the professions and industry. Miller LC Hosp Formul; 1976 Mar; 11(3):151-5. PubMed ID: 1026682 [No Abstract] [Full Text] [Related]
24. [Control of drugs in foreign countries]. Buriánek J; Parrák V Cesk Farm; 1973 Jul; 22(6):247-53. PubMed ID: 4732551 [No Abstract] [Full Text] [Related]
25. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals. Hung JC J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115 [No Abstract] [Full Text] [Related]
26. Biopharmaceutic equivalency and the role of the Food & Drug Administration. Hodges RM Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859 [No Abstract] [Full Text] [Related]
27. World agencies try to stem flood of fake drugs. Surendran A Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401 [No Abstract] [Full Text] [Related]
28. Recommended methods for compounding intravenous admixtures in hospitals. Am J Hosp Pharm; 1975 Mar; 32(3):261-70. PubMed ID: 1136973 [TBL] [Abstract][Full Text] [Related]
29. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]
30. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
31. Parenteral suspensions. Nash RA Bull Parenter Drug Assoc; 1972; 26(2):91-4. PubMed ID: 5012208 [No Abstract] [Full Text] [Related]
32. Pharmaceutical analysis: key to drug quality and control. Florey KG; Brewer GA Am Pharm; 1981 Aug; NS21(8):30-5. PubMed ID: 7270421 [No Abstract] [Full Text] [Related]
33. The regulation of biopharmaceuticals. Weisbroth N Qual Assur; 1993; 2(1-2):147-51. PubMed ID: 8156202 [No Abstract] [Full Text] [Related]
34. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products. Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700 [No Abstract] [Full Text] [Related]
35. Recommendations to pharmacists for solving problems with large-volume parenterals. Am J Hosp Pharm; 1976 Mar; 33(3):231-6. PubMed ID: 816199 [No Abstract] [Full Text] [Related]
36. Planning for change. Hansen DC Bull Parenter Drug Assoc; 1969; 23(1):1-5. PubMed ID: 5765717 [No Abstract] [Full Text] [Related]
37. Expired drugs are not dead drugs. Torigian PC Am J Hosp Pharm; 1993 Mar; 50(3):448. PubMed ID: 8442459 [No Abstract] [Full Text] [Related]
38. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association. Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805 [No Abstract] [Full Text] [Related]
39. The intensified drug inspection program: procedures and results. Clevenger WL Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888 [No Abstract] [Full Text] [Related]